Literature DB >> 35876942

In-hospital prognosis of malignancy-related pulmonary embolism: an analysis of the national inpatient sample 2016-2018.

Dae Yong Park1, Seokyung An2, Ibrahim Kashoor3, Olisa Ezegwu3, Shweta Gupta4,5.   

Abstract

A substantial proportion of patients with malignancy develop pulmonary embolism (PE), which significantly worsens the prognosis and ranks as one of the leading causes of mortality in these patients. This retrospective study aimed to examine prognosis of PE in 17 different types of malignancies. All hospitalizations for a primary diagnosis of PE, were identified from the National Inpatient Sample from 2016 to 2018 and divided into those with and without malignancies. Propensity score matching was performed with malignancy as the dependent variable and 23 clinically relevant covariates. Malignancy was stratified into 17 different types of cancer, for which the odds of in-hospital mortality were calculated. After propensity score matching, 82,970 hospitalizations for PE each were allocated into those with and without malignancy groups. PE in all types of malignancies had significantly higher odds of in-hospital mortality compared to PE without malignancy (OR 2.27, 95% CI 2.03-2.54). When stratified to types, esophageal cancer (OR 4.05, 95% CI 2.77-5.92) was associated with the highest odds of in-hospital mortality, followed by gastric (OR 3.41, 95% CI 2.25-5.16) and ovarian cancer (OR 2.95, 95% CI 2.12-4.13). On sensitivity analysis, only PE in esophageal and lung cancer was associated with higher odds of in-hospital mortality compared to PE in all other malignancies combined. Hospitalizations for PE in patients with malignancy were associated with higher odds of in-hospital mortality than those without malignancy. Esophageal cancer had the highest odds of in-hospital mortality, followed by gastric, ovarian, and lung cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Cancer; Malignancy; Mortality; PE; Pulmonary embolism

Year:  2022        PMID: 35876942     DOI: 10.1007/s11239-022-02684-8

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   5.221


  41 in total

1.  Pulmonary embolism as a cause of death in patients who died with cancer.

Authors:  Paul D Stein; Afzal Beemath; Frederick A Meyers; Fadi Kayali; Elias Skaf; Ronald E Olson
Journal:  Am J Med       Date:  2006-02       Impact factor: 4.965

Review 2.  Management of venous thromboembolism in patients with cancer.

Authors:  G Agnelli; M Verso
Journal:  J Thromb Haemost       Date:  2011-07       Impact factor: 5.824

3.  Malignancies, prothrombotic mutations, and the risk of venous thrombosis.

Authors:  Jeanet W Blom; Carine J M Doggen; Susanne Osanto; Frits R Rosendaal
Journal:  JAMA       Date:  2005-02-09       Impact factor: 56.272

Review 4.  Cancer-associated thrombosis: the when, how and why.

Authors:  Caio J Fernandes; Luciana T K Morinaga; José L Alves; Marcela A Castro; Daniela Calderaro; Carlos V P Jardim; Rogerio Souza
Journal:  Eur Respir Rev       Date:  2019-03-27

5.  Predictors of venous thromboembolism in patients with advanced common solid cancers.

Authors:  Isaac E Hall; Martin S Andersen; Harlan M Krumholz; Cary P Gross
Journal:  J Cancer Epidemiol       Date:  2010-02-16

6.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Incidence and mortality of venous thrombosis: a population-based study.

Authors:  I A Naess; S C Christiansen; P Romundstad; S C Cannegieter; F R Rosendaal; J Hammerstrøm
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

8.  Deep vein thrombosis and pulmonary embolism in two cohorts: the longitudinal investigation of thromboembolism etiology.

Authors:  Mary Cushman; Albert W Tsai; Richard H White; Susan R Heckbert; Wayne D Rosamond; Paul Enright; Aaron R Folsom
Journal:  Am J Med       Date:  2004-07-01       Impact factor: 4.965

Review 9.  Assessing risk of venous thromboembolism in the patient with cancer.

Authors:  Alok A Khorana; Gregory C Connolly
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

Review 10.  Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis.

Authors:  Freesia Horsted; Joe West; Matthew J Grainge
Journal:  PLoS Med       Date:  2012-07-31       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.